# Hereditary Alpha-Tryptasemia and Mastocytosis: What We Know and What We Need To Learn

**Authors:** Tiago A. Rama, Theo Gulen

PMC · DOI: 10.1007/s11882-026-01262-9 · Current Allergy and Asthma Reports · 2026-03-09

## TL;DR

This paper reviews the connection between hereditary alpha-tryptasemia and mastocytosis, highlighting recent findings and unresolved questions about their relationship.

## Contribution

The paper provides a comprehensive review of recent advances and controversies in the relationship between HαT and mastocytosis.

## Key findings

- HαT is a common genetic trait linked to elevated baseline tryptase levels.
- HαT is frequently found in mastocytosis patients, but the clinical significance remains unclear.
- More research is needed to clarify how HαT influences mast cell disorders.

## Abstract

This review aims to elucidate the evolving relationship between hereditary alpha-tryptasemia (HαT) and mastocytosis, emphasizing recent advances in understanding shared pathophysiological mechanisms, diagnostic challenges, and clinical implications.

HαT is a common genetic trait caused by increased copy numbers of the TPSAB1 gene encoding alpha-tryptase. It accounts for most elevated serum baseline tryptase (SBT) levels (> 8 ng/mL) seen in clinical allergy practice. Diagnosis is established through tryptase genotyping—often referred to as “tryptase copy number variation (CNV) testing”.

Over the past decade, studies have reported a high prevalence of HαT among individuals with mastocytosis, prompting routine screening. However, the nature of this association remains controversial. While some studies suggest a potential link—most notably an increased risk of severe anaphylaxis—others have failed to show consistent correlations in pathophysiology or clinical outcomes. The evidence base is still evolving, and inconsistencies across studies underscore the need for cautious interpretation.

HαT complicates the clinical assessment of mastocytosis by influencing baseline tryptase levels and potentially modulating symptom severity, though its clinical impact remains under investigation. Further research is needed to clarify the extent and nature of HαT’s contribution to mastocytosis and related mast cell disorders.

## Linked entities

- **Genes:** TPSAB1 (tryptase alpha/beta 1) [NCBI Gene 7177]
- **Diseases:** mastocytosis (MONDO:0007950)

## Full-text entities

- **Genes:** IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, TPSAB1 (tryptase alpha/beta 1) [NCBI Gene 7177] {aka TPS1, TPS2, TPSB1, TPSB2, Tryptase-2}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, TPSG1 (tryptase gamma 1) [NCBI Gene 25823] {aka PRSS31, TMT, trpA}, TPSB2 (tryptase beta 2) [NCBI Gene 64499] {aka TPS2, tryptaseB, tryptaseC}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, ADRA2B (adrenoceptor alpha 2B) [NCBI Gene 151] {aka ADRA2L1, ADRA2RL1, ADRARL1, ALPHA2BAR, FAME2, alpha-2BAR}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, ADGRE2 (adhesion G protein-coupled receptor E2) [NCBI Gene 30817] {aka CD312, CD97, EMR2, VBU}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, TPSD1 (tryptase delta 1) [NCBI Gene 23430] {aka MCP7-LIKE, MCP7L1, MMCP-7L}, F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150] {aka GPR11, PAR2}, TMPRSS11D (transmembrane serine protease 11D) [NCBI Gene 9407] {aka ASP, HAT}
- **Diseases:** MCAS (MESH:D000090267), Asthma (MESH:D001249), abdominal pain (MESH:D015746), myeloid neoplasms (MESH:D009369), Hymenoptera stings (MESH:D001733), skin lesions (MESH:D012871), Bone pain (MESH:D010146), hereditary (MESH:D009386), MCL (MESH:D007946), syncope (MESH:D013575), Mastocytosis (MESH:D008415), headache (MESH:D006261), inflammation (MESH:D007249), Anaphylaxis (MESH:D000707), ASM (MESH:D034721), disorder (MESH:D009358), pruritus (MESH:D011537), CM (MESH:D034701), hematologic neoplasm (MESH:D019337), hypotension (MESH:D007022), diarrhoea (MESH:D003967), gastrointestinal dysmotility (MESH:D015154), fatigue (MESH:D005221), atopy (MESH:C564133), nausea (MESH:D009325), urticaria (MESH:D014581), UP (MESH:D014582), Hereditary Alpha-Tryptasemia (MESH:C000715748), osteoporosis (MESH:D010024), HVA (MESH:D000092422), Mast Cell Disorders (MESH:D000090362), vascular leak (MESH:D019559), BMM (MESH:D001855), gastrointestinal discomfort (MESH:D005767), cardiovascular symptoms (MESH:D002318), POTS (MESH:D054972), flushing (MESH:D005483), angioedema (MESH:D000799), maculopapular lesions (MESH:D010267), cognitive disturbances (MESH:D003072), SBT (MESH:D012713), FIA (MESH:D000092202), Allergy (MESH:D004342), joint hypermobility (MESH:D007593), DIA (MESH:D000081015)
- **Chemicals:** histamine (MESH:D006632), SBT (-), heparin (MESH:D006493)
- **Species:** Homo sapiens (human, species) [taxon 9606], Hymenoptera (hymenopterans, order) [taxon 7399]
- **Mutations:** D816V

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12971857/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12971857/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12971857/full.md

---
Source: https://tomesphere.com/paper/PMC12971857